- Q1 1
- Q2 1
- Q3 1
- Q4 0
Academician
DİLRUBA TIRPANLAR
ARAŞTIRMA GÖREVLİSİ
Academic summary
YÖKSİS and OpenAlex counted separately.
Articles
4
YÖKSİS4
OpenAlex0
Projects
0
Books
0
Proceedings
1
Citation impact
OpenAlex YÖKSİS articles matched in OpenAlex: 4
h-index
2
Percentile in Türkiye: 29
#291 of 595 at their university by h-index
- i10-index
- 0
- Total citations
- 7 Top 74% in Türkiye
- Per article
- 1.8
- FWCI
- 1.22 1.00 = world average
- World top 1%
- 0
- World top 10%
- 1
Most cited articles
h-index and citations are computed from the citation counts of this academic’s YÖKSİS articles matched in OpenAlex (not Google Scholar, WoS or Scopus). Unmatched articles are not included. h-index on the OpenAlex author profile: 1.
Field ranking
YÖKSİS ?-
Main field Sağlık Bilimleri Temel AlanıPoints rank #25,273/ 43,834 top 57.7%Score 2.85 journal 2.6 · OA add 0.25
- Article rank26,626/43,834
- Scopus rank24,660/43,834
- WoS rank24,450/43,834
- YÖKSİS4
- Scopus3
- WoS3
-
Side field Tıbbi BiyokimyaPoints rank #638/ 896 top 71.2%Score 2.85 journal 2.6 · OA add 0.25
- Article rank654/896
- Scopus rank631/896
- WoS rank628/896
- YÖKSİS4
- Scopus3
- WoS3
Index quartiles
?- Q1 1
- Q2 1
- Q3 1
- Q4 0
0 articles
- Top 1% 0
- Top 10% 1
- Avg 52.2%
- n 4
Other counts
Scopus (SJR)
- YÖKSİS rows 3
WoS (JCR)
- YÖKSİS rows 3
Articles
Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.
Journals with publications
4 journals
Article list
- 2026 Design, synthesis and evaluation of novel oxadiazole-based compounds as potential Rac1 inhibitors against breast cancer YÖKSİS SJR Q1 JCR Q1 OpenAlex 20.4%
- 2025 Isolation of anti-inflammatory and cytotoxic secondary metabolites from Valeriana phu and evaluation of their mechanisms of action YÖKSİS SJR Q2 JCR Q2 OpenAlex top 10% OpenAlex 90.9%
- 2025 Synthesis and Biological Evaluation of Novel N-Substituted 3-Methylindole Derivatives YÖKSİS OpenAlex 19.6%
- 2023 Tumor microenvironment highlighting tumor-associated macrophages and immune cells YÖKSİS SJR Q3 JCR Q3 OpenAlex 77.9%